Hjem › Brystkreft › Nevada
Kliniske studier for Brystkreft i Nevada
19 studier for Brystkreft søker deltakere på steder i Nevada.
Byer i Nevada
Offisiell studietekst (engelsk)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Cancer Care Specialists, Reno
RekruttererFase 3
Alder 18 til 100 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Carson Tahoe Regional Medical Center, Carson City
- Comprehensive Cancer Centers of Nevada - Henderson, Henderson
- Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson
- og 25 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Cancer Care Specialists, Reno
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06369285A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Optum Care Cancer Center ( Site 0050), Las Vegas
- Renown Regional Medical Center ( Site 0041), Reno
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06966700A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Renown Regional Medical Center, Reno
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT03424005A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Reno
RekruttererFase 3
Alder 18 til 130 · Alle kjønn · Oppdatert 8. sep. 2026 · NCT07647328Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Renown Health Medical Oncology, Reno
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06982521Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Cancer Care Specialist of Reno, Reno
RekruttererObservasjonsstudie
Alder 18 til 99 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT07211178Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Carson Tahoe Regional Medical Center, Carson City
- Comprehensive Cancer Centers of Nevada - Henderson, Henderson
- Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson
- og 25 flere
RekruttererFase 3
Alder 18 til 60 · Kvinner · Oppdatert 2. sep. 2026 · NCT05879926A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Comprehensive Cancer Centers of Nevada, Las Vegas
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 28. aug. 2026 · NCT07029399A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- Comprehensive Cancer Centers of Nevada, Las Vegas
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 21. aug. 2026 · NCT06764940Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Comprehensive Cancer Centers of Nevada, Henderson
RekruttererFase 3
Alder 18 til 100 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT05232916A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Comprehensive Cancer Centers of Nevada, Las Vegas
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. jun. 2026 · NCT05377996Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Renown Regional Medical Centre, Reno
- Cancer Care Specialists, Reno
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. jun. 2026 · NCT05696626A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Comprehensive Cancer Centers of Nevada, Henderson
- Comprehensive Cancer Centers of Nevada, Henderson
- Comprehensive Cancer Centers of Nevada, Las Vegas
- og 3 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 6. mai 2026 · NCT07062965De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- OptumCare Cancer Care at Seven Hills, Henderson
- OptumCare Cancer Care at Charleston, Las Vegas
- Radiation Oncology Centers of Nevada Central, Las Vegas
- og 8 flere
RekruttererFase 3
Alder 50 til 70 · Alle kjønn · Oppdatert 23. apr. 2026 · NCT04852887A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
- Comprehensive Cancer Centers of Nevada, Las Vegas
RekruttererFase 1
Alder 18 og eldre · Kvinner · Oppdatert 22. apr. 2026 · NCT05683418Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- OptumCare Cancer Care at Seven Hills, Henderson
- OptumCare Cancer Care at Charleston, Las Vegas
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 17. mar. 2026 · NCT06418204First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Renown Regional Medical Center, Reno
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2025 · NCT05216432Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.